



CLAIMS:

1. An oligomeric compound according to the following chemical structure:



(SEQ ID NO: 3379), or a salt thereof.

2. An oligomeric compound according to the following chemical structure:




(SEQ ID NO: 3379).

3. An oligomeric compound comprising a modified oligonucleotide and a conjugate group according to the following chemical notation: (THA- GalNAc₃)_o Gks ^mCks Gks Gds Ads Ads Tds ^mCds Ads ^mCds ^mCds Ads Ads Gks Gks Ak (SEQ ID NO: 3379), wherein:


A = an adenine nucleobase,
^mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
k = a cEt modified sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and

(THA-GalNAc₃)_o =




4. The oligomeric compound of claim 1, which is the sodium salt or the potassium salt.

5. An oligomeric compound according to the following chemical structure:



(SEQ ID NO: 5006), or a salt thereof.

6. An oligomeric compound according to the following chemical structure:




(SEQ ID NO: 5006).

7. An oligomeric compound comprising a modified oligonucleotide and a conjugate group according to the following chemical notation: (THA- GalNAc₃)_o Gks ^mCks Aks ^mCds Uys Tds Tds Ads Tds Tds Gds Ads Gds Tks Tks mCk (SEQ ID NO: 5006), wherein:

- A = an adenine nucleobase,
- mC = a 5-methyl cytosine nucleobase,
- G = a guanine nucleobase,
- T = a thymine nucleobase,

U = a uracil nucleobase,
 k = a cEt modified sugar moiety,
 y = a 2'-O-methyl modified ribosyl sugar moiety,
 d = a 2'-β-D-deoxyribosyl sugar moiety,
 s = a phosphorothioate internucleoside linkage, and
 (THA- GalNAc₃)_o =



8. The oligomeric compound of claim 5, which is the sodium salt or the potassium salt.
9. A population of oligomeric compounds of any one of claims 1-8, wherein all of the phosphorothioate internucleoside linkages are stereorandom.
10. A pharmaceutical composition comprising the oligomeric compound of any one of claims 1-8, or the population of oligomeric compounds of claim 9, and a pharmaceutically acceptable diluent.
11. The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable diluent is sterile saline or sterile water.
12. The pharmaceutical composition of claim 11, wherein:
 - (i) the pharmaceutical composition consists of the oligomeric compound and sterile saline or sterile water; or
 - (ii) the pharmaceutical composition consists essentially of the oligomeric compound and sterile saline or sterile water.
13. The oligomeric compound of any of claims 1-8, the population of oligomeric compounds of claim 9, or the pharmaceutical composition of any one of claims 10-12, for use in therapy.
14. Use of the oligomeric compound of any of claims 1-8, the population of oligomeric compounds of claim 9, or the pharmaceutical composition of any one of claims 10-12, in the manufacture of a medicament for

ameliorating or preventing a thromboembolic condition, wherein a therapeutically effective amount of the oligomeric compound, the population of oligomeric compounds, or the pharmaceutical composition is to be administered to a subject in need thereof.

15. The use of claim 14, wherein the thromboembolic condition is selected from myocardial infarction (MI), stroke, limb ischemia and necrosis, venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE).
16. The use of claim 14 or claim 15, wherein at least one symptom of the thromboembolic condition is ameliorated.
17. The use of claim 16, wherein the symptom is pain, shortness of breath, heart burn, cold sweat, fatigue, lightheadedness, dizziness, swelling, cramping, and death.
18. The use of any one of claims 14-17, further comprising identifying the subject as having the thromboembolic condition or as having a risk factor for having the thromboembolic condition.
19. The use of claim 18, wherein the risk factor is surgery, malignancy, pregnancy, aging, use of oral contraceptives, immobility, sepsis, a mechanical heart valve, valvular heart disease, atrial fibrillation, atherosclerosis, antiphospholipid syndrome, an inherited clotting disorder, or an acquired prothrombotic clotting disorder.
20. Use of the oligomeric compound of any of claims 1-8, the population of oligomeric compounds of claim 9, or the pharmaceutical composition of any one of claims 10-12, in the manufacture of a medicament for ameliorating or preventing hereditary angioedema, wherein a therapeutically effective amount of the oligomeric compound, the population of oligomeric compounds, or the pharmaceutical composition is to be administered to a subject.